Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Airbus Joins Air India A320 Altitude Drop Probe 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Novo Nordisk A/S (NYSE: NVO) increased its full-year 2026 guidance after strong demand for its obesity and diabetes treatments continued to drive growth, despite ongoing pricing pressure in key markets. The Danish pharmaceutical giant said higher expectations for its GLP-1 drug portfolio, including Wegovy and Ozempic, supported the improved forecast.
The company now expects adjusted sales and operating profit to decline between 4% and 12% at constant exchange rates in 2026, a narrower drop compared to its previous outlook. Following the announcement, Novo Nordisk shares climbed 7% during early trading in Copenhagen as investors reacted positively to the updated guidance.
Novo Nordisk reported first-quarter operating profit of 59.6 billion Danish crowns ($8.6 billion), marking a 65% increase from the previous year. The surge was mainly driven by a one-time reversal connected to the U.S. 340B Drug Pricing Program. However, adjusted operating profit fell 6% to 32.9 billion crowns, while adjusted sales slipped 4% to 70.1 billion crowns due to lower realized prices.
Demand for obesity drugs remained a major growth driver. Sales of obesity treatments increased 22% at constant exchange rates, fueled by strong adoption of Wegovy. The newly launched Wegovy pill version in the United States generated 2.3 billion Danish crowns in quarterly sales, highlighting continued momentum in the weight-loss drug market.
In the United States, adjusted sales declined 11% because of pricing pressure, while international sales rose 6% on stronger volumes. Analysts at Morgan Stanley noted that Novo Nordisk’s guidance still appears conservative and suggested the company could finish the year in the upper half of its projected range.
Novo Nordisk said broader access to GLP-1 treatments and ongoing product launches are expected to support future growth, although competition, lower drug prices, and upcoming patent expirations may continue to pressure results throughout the year.
